A QALY is [still] a QALY is [still] a QALY?
Loading...
Date issued
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Reuse License
Description of rights: CC-BY-4.0
Abstract
Despite clinical evidence of drug superiority, therapeutic modalities, like combination immunotherapy, are mostly
considered cost-ineffective due to their high costs per life year(s) gained. This paper, taking an ethical stand,
reevaluates the standard cost-effectiveness analysis with that of the more recent justice-enhanced methods and
concludes by pointing out the shortcomings of the current methodologies.
